Thalagen™ is the brand name for EGT’s gene therapy treatment for beta thalassemia, also referred to as Cooley’s anemia. To date there is no curative therapy for thalassemia, a disease characterized by the cells of the bone marrow having an inability to produce normal hemoglobin.
Trichostatin A (TSA) was originally reported (1976) as a fungistatic antibiotic obtained from a culture broth of Streptomyces platensis. In 1987, its anti-proliferative activity was reported, and in 1990, TSA was found to cause an accumulation of acetylated histones in a variety of mammalian tumor
CG-1521 (7-phenyl-2, 4, 6-hepta-trienoyl hydroxamic acid) is an inhibitor of histone deacetylase (HDAC) in the final stages of pre-clinical development. The compound has been shown to inhibit cell proliferation of both solid and hematological cancer cells and has been extensively studied in neuroblastoma and prostate cancer models.